A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer

BACKGROUND: Gefitinib is an oral EGFR tyrosine kinase inhibitors which may act as a radiosensitizer. PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by...

Descripción completa

Detalles Bibliográficos
Autores principales: Levy, Antonin, Bardet, Etienne, Lacas, Benjamin, Pignon, Jean-Pierre, Adam, Julien, Lacroix, Ludovic, Artignan, Xavier, Verrelle, Pierre, Le Péoux, Cécile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362534/
https://www.ncbi.nlm.nih.gov/pubmed/27764781
http://dx.doi.org/10.18632/oncotarget.12741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362534/
https://www.ncbi.nlm.nih.gov/pubmed/27764781
http://dx.doi.org/10.18632/oncotarget.12741

Ejemplares similares